Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus
- 1 April 2004
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (4), 531-540
- https://doi.org/10.1016/s0149-2918(04)90055-0
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Preference and resource utilization in elderly patients: InnoLet® versus vial/syringeDiabetes Research and Clinical Practice, 2004
- Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patientsDiabetic Medicine, 2002
- Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 DiabetesDiabetes Care, 2002
- Recombinant DNA Technology in the Treatment of Diabetes: Insulin AnalogsEndocrine Reviews, 2001
- Patient and physician satisfaction with the Humulin®/Humalog® Pen, a new 3.0-mL prefilled pen device for insulin deliveryClinical Therapeutics, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringeClinical Therapeutics, 1998
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993